PNaktide reverses metabolic reprogramming and disease progression of ATP1A1-deficiency clear cell renal cell carcinoma.

ABSTRACT: ATP1A1 has been reported to exhibit differential expression across various tumors; however, its specific role in clear cell renal cell carcinoma (ccRCC) remains uncharted. This study investigates the role of ATP1A1 in ccRCC, assessing its potential as a prognostic marker and therapeutic target. Through database analysis and clinical sample evaluation, we found that ATP1A1 expression is significantly downregulated in ccRCC and closely correlates with poor patient prognosis. Both in vitro and in vivo experiments further confirmed that ATP1A1 exerts tumor-suppressive effects by inhibiting SRC kinase activity. Additionally, co-expression gene analysis suggests that ATP1A1 may regulate ccRCC development by targeting metabolic reprogramming. We also discovered that the overexpression of ATP1A1 i

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC12702778 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature